Irinotecan and Capecitabine in Treating Patients With Solid Tumors
Part of paid clinical trials in The Bronx, New York.
- Sponsor
- Montefiore Medical Center
- Study ID
- NCT00003867
- Phase
- PHASE1
- Status
- Completed
Conditions
- Cancer
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - 120 Years
- Healthy Volunteers
- Not accepted
Interventions
- capecitabine — DRUG
- irinotecan hydrochloride — DRUG
Study Details
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: Phase I trial to study the effectiveness of irinotecan and capecitabine in treating patients who have solid tumors that have not responded to previous treatment.
Key Dates
- Start date
- Mar 31, 1999
- Status verified
- Sep 2018
- Primary completion
- Mar 31, 2003
- Completion
- Mar 31, 2003
Study Design
- Enrollment
- 30 participants (actual)
- Primary purpose
- TREATMENT
Locations (1)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| Albert Einstein Comprehensive Cancer Center | The Bronx | New York | 10461 | - |
Find similar trials in The Bronx, NY
By research site
Related Studies
- Childhood Cancer Survivor StudyRecruiting · St. Jude Children's Research Hospital · Birmingham, Alabama
- Caris Biorepository Research ProtocolRecruiting · Caris Science, Inc. · Mobile, Alabama
- Cryopreservation of Ovarian TissueRecruiting · Weill Medical College of Cornell University · New York, New York
- Quality of Life (QoL) Assessment in Cancer Patients and Survivors With Dermatologic Conditions Using Dermatologic QoL InstrumentsRecruiting · Memorial Sloan Kettering Cancer Center · Basking Ridge, New Jersey